Exegenesis Bio Inc.: Another Chapter 18A Biotech IPO Bid Falls Short! Listing Application Lapses Upon Expiry

NewTimeSpace News: The listing application filed by Exegenesis Bio Inc. with HKEX on 14 January 2026 has lapsed as the six-month validity term expired. CCB International served as the original sole sponsor.

Founded in 2019, the Company is a biopharmaceutical enterprise concentrating on gene therapies and oligonucleotide medicines. It has independently developed two technology platforms: AAVarta, an AI-assisted AAV capsid evolution discovery platform, and SODA, a silencing oligonucleotide design approach.

Lead candidate EXG001-307 for SMA Type 1 is a single-dose AAV-based gene therapy engineered to drive expression within the central nervous system while minimising peripheral tissue expression. It addresses major safety limitations of existing gene therapies and is expected to become a best-in-class treatment for spinal muscular atrophy Type 1. Two other key candidates EXG102-031 and EXG202 are single-dose AAV gene therapies designed to overcome limitations of current anti-VEGF biologics.
According to Frost & Sullivan data, the global SMA therapeutics market is projected to expand from USD4.64 billion in 2024 to USD9.45 billion by 2035. Meanwhile, the global pharmaceutical market for fundus neovascular diseases is forecast to grow from USD15.6 billion in 2024 to USD55.8 billion by 2035.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.